Everolimus tablets for patients with subependymal giant cell astrocytoma

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 14, 2011, Pages 2265-2269

  Turner, Scott G ^a   Peters, Katherine B ^a   Vredenburgh, James J ^a   Desjardins, Annick ^a   Friedman, Henry S ^a   Reardon, David A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

astrocytoma; everolimus; low grade glioma; mTOR inhibitor; tuberous sclerosis

Indexed keywords

EVEROLIMUS; HAMARTIN; RAPAMYCIN; TUBERIN;

AMINOTRANSFERASE BLOOD LEVEL; ANGIOMYOLIPOMA; ARTICLE; ASTROCYTOMA; BREAST CANCER; CANCER SURGERY; CELL GROWTH; CELL PROLIFERATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FEVER; DRUG TOLERABILITY; EAR INFECTION; GIANT CELL TUMOR; GRAFT REJECTION; HEMANGIOFIBROMA; HUMAN; HYPERLIPIDEMIA; KIDNEY CANCER; LIVER CELL CARCINOMA; LYMPHOMA; MENTAL DEFICIENCY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; QUALITY OF LIFE; SEIZURE; SIDE EFFECT; SINUSITIS; STOMACH CANCER; STOMATITIS; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; SUBEPENDYMOMA; TREATMENT DURATION; TUBEROUS SCLEROSIS; UPPER RESPIRATORY TRACT INFECTION;

ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; HUMANS; PROTEINS; SIROLIMUS; TABLETS; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 80052615706     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.601742     Document Type: Article

References (31)

1. Krueger DA, Franz DN. Current anagement of tuberous sclerosis complex. Paediatr Drugs 2008;10:299-313
2. Braffman BH, Bilaniuk LT, Naidich TP, et al. MR imaging of tuberous sclerosis: pathogenesis of this phakomatosis, use of gadopentetate dimeglumine, and literature review. Radiology 1992;183:227-38
3. Nabbout R, Santos M, Rolland Y, et al. Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis. J Neurol Neurosurg Psychiatry 1999;66:370-5 (Pubitemid 29103492)
4. Cuccia V, Zuccaro G, Sosa F, et al. Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst 2003;19:232-43 (Pubitemid 36798785)
5. Adriaensen ME, Schaefer-Prokop CM, Stijnen T, et al. Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol 2009;16:691-6
6. Franz DN, de Vries PJ, Crino PB. Giant cell astrocytomas in tuberous sclerosis complex. Arch Dis Child 2009;94:75-6
7. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998;13:624-8 (Pubitemid 29035481)
8. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355:1345-56
9. van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997;277:805-8 (Pubitemid 27366729)
10. The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305-15
11. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45 (Pubitemid 39071573)
12. Inoki K, Li Y, Xu T, et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003;17:1829-34 (Pubitemid 36944560)
13. Benvenuto G, Li S, Brown SJ, et al. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 2000;19:6306-16 (Pubitemid 32641844)
14. Henry KW, Yuan X, Koszewski NJ, et al. Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members. J Biol Chem 1998;273:20535-9 (Pubitemid 28377623)
15. Chan JA, Zhang H, Roberts PS, et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 2004;63:1236-42 (Pubitemid 39603395)
16. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008;412:179-90 (Pubitemid 351758225)
17. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006;25:6436-46 (Pubitemid 44582287)
18. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006;59:490-8 (Pubitemid 43358069)
19. Koenig MK, Butler IJ, Northrup H. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 2008;23:1238-9
20. Plas DR, Thomas G. Tubers and tumors: rapamycin therapy for benign and malignant tumors. Curr Opin Cell Biol 2009;21:230-6
21. Kenerson H, Dundon TA, Yeung RS. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 2005;57:67-75 (Pubitemid 40039895)
22. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358:140-51
23. Houghton PJ. Everolimus. Clin Cancer Res 2010;16:1368-72
24. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363:1801-11
25. Chang SM, Kuhn J, Wen P, et al. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Investigational New Drugs 2004:22;427-35 (Pubitemid 39619819)
26. Chang SM,Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investigational New Drugs 2005:23;357-61 (Pubitemid 40980358)
27. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 2005:23;5294-304 (Pubitemid 46206983)
28. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLOS Medicine V.5(1):e8, 2008, Jan 22
29. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of MTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008:118;3065-74
30. Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiother Oncol 2011;98:1-14
31. Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010;60:166-93